

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A method of protecting a male patient from possible adverse effects on the prostate of a treatment involving inhibition of the SHH-signalling pathway in the patient, the method comprising:

suppressing testosterone or its effect in the male patient, whereby said suppressing is effective in protecting the male patient from possible adverse effects on the prostate caused by the treatment involving inhibition of the SHH-signalling pathway.

2. (Currently amended) A method of treating a proliferative disease in a male patient the method comprising inhibiting the SHH-signalling pathway and suppressing testosterone or its effect in the male patient, wherein the proliferative disease is a cancer in which SHH-signalling plays a role in its growth and/or differentiation, and the cancer is not prostate cancer.

3. (Currently amended) A method according to Claim 2 wherein said inhibiting the SHH-signalling pathway comprises administering ~~is inhibited by the administration of~~ cyclopamine or a derivative thereof to the male patient.

4. (Previously presented) A method according to Claim 2 wherein testosterone is suppressed to castrate levels.

5. (Currently amended) A method according to Claim 2 wherein said suppressing testosterone or its effect comprises ~~is suppressed by~~ administering any one or more of a GnRH antagonist, a GnRH agonist, an androgen antagonist or a 5 α reductase inhibitor to the patient.

6-7. (Canceled)

8. (Currently amended) A method according to Claim 2 wherein the proliferative disease is any of basal cell carcinoma, medulloblastoma, or glioblastoma ~~or prostate cancer.~~

9-17. (Canceled)

18. (Original) A therapeutic system for treating a patient, the system comprising an inhibitor of the SHH-signalling pathway and a compound which suppresses testosterone or its effect in the patient.

19. (Original) A composition comprising an inhibitor of the SHH-signalling pathway and a compound which suppresses testosterone or its effect in a patient.

20. (Canceled)

21. (Original) A pharmaceutical composition comprising an inhibitor of the SHH-signalling pathway and a compound which suppresses testosterone or its effect in a patient and a pharmaceutically acceptable carrier.

22-23. (Canceled)

24. (Currently amended) A method according to Claim 1 wherein the treatment involving inhibition of the SHH-signalling pathway ~~is inhibited by the~~ comprises administration of cyclopamine or a derivative thereof to the male patient.

25. (Previously presented) A method according to Claim 1 wherein testosterone is suppressed to castrate levels.

26. (Currently amended) A method according to Claim 1 wherein said suppressing testosterone or its effect ~~is suppressed by~~ comprises administering any one or more of a GnRH antagonist, a GnRH agonist, an androgen antagonist or a 5 α reductase inhibitor to the male patient.

27-29. (Canceled)